Can You Stop Zepbound Cold Turkey? Labels and Trials
In this guide
This article is for information only and is not medical advice. Talk to your prescriber or a qualified professional.
Can you stop Zepbound cold turkey? The Zepbound label, like the Wegovy and Ozempic labels, does not give a tapering schedule for stopping, and it does not describe a withdrawal syndrome. It does say to stop right away in some safety situations, such as suspected pancreatitis or a serious allergic reaction. In the trials that stopped treatment all at once, people regained much of the weight they had lost. No trial we found compared tapering with stopping outright. Whether to stop, and how, is a decision to make with your prescriber, not on your own.
About Dosinha: a shot log, reminders, injection-site rotation, weight and water are free forever. See what is free and what Pro adds.
Key points
- The labels for Zepbound, Wegovy and Ozempic give a schedule for starting and stepping up, not for stopping.
- In the label situations where stopping is required, such as suspected pancreatitis, the instruction is to stop, not to taper.
- Withdrawal trials stopped the medicine outright and saw substantial weight regain. They did not test tapering.
- Tell your prescriber before you stop, so they can plan follow-up and review your other medicines.
This page is part of our guide to what happens when you stop taking a GLP-1, which has the full trial numbers.
What the labels say about stopping
What they include. According to the Zepbound and Wegovy prescribing information, the medicine should be stopped if pancreatitis is suspected or if a serious allergic reaction occurs. The Zepbound label says to stop when a pregnancy is recognized. The Wegovy label says to stop at least 2 months before a planned pregnancy because semaglutide stays in the body a long time. The Wegovy label also says to stop if resting heart rate stays raised.
What they do not include. We read the current labels for Zepbound, Wegovy and Ozempic. None of them gives a dose-reduction schedule for stopping, and none describes a withdrawal syndrome. The dose steps in the labels are for starting treatment. The Zepbound label explains that the gradual start is to reduce the risk of stomach side effects.
So the official labels do not offer a plan for how to taper off a GLP-1. Your prescriber and pharmacist set your plan.
The medicine leaves your body slowly either way
Even an abrupt stop does not mean the medicine is gone the next day. According to the labels:
| Medicine | Ingredient | Half-life in the label | Label note |
|---|---|---|---|
| Zepbound | tirzepatide | About 5 days (5 to 6 days in people with overweight or obesity) | See the label’s pharmacokinetics section |
| Wegovy | semaglutide | About 1 week | Present in the blood for about 5 to 7 weeks after the last injection |
| Ozempic | semaglutide | About 1 week | Present in the blood for about 5 weeks after the last dose |
This is label pharmacology, not a prediction of how you will feel.
What the withdrawal trials found
Three studies looked at what happened when GLP-1 treatment stopped all at once:
| Study | Setup | What happened after stopping |
|---|---|---|
| SURMOUNT-4, tirzepatide | 670 adults took tirzepatide for 36 weeks, then continued or switched to placebo for 52 weeks | Placebo group gained a mean 14.0%; the continued group lost a further 5.5% |
| STEP 4, semaglutide 2.4 mg | 803 adults took semaglutide for 20 weeks, then continued or switched to placebo for 48 weeks | Placebo group gained 6.9%; the continued group lost a further 7.9% |
| STEP 1 extension, semaglutide 2.4 mg | 327 adults followed for a year after treatment and lifestyle support ended at week 68 | Regained about two-thirds of the weight lost |
In SURMOUNT-4, 89.5% of people who continued tirzepatide kept at least 80% of their earlier weight loss at week 88, compared with 16.6% of those switched to placebo. All of these participants were adults with obesity, or overweight plus a weight-related condition, without diabetes. These are averages. They are not predictions for you, and none of these trials tested a gradual taper.
Ozempic and stopping
People also ask whether they can stop taking Ozempic cold turkey. Ozempic is semaglutide labeled for type 2 diabetes. Like the others, its label has a step-up schedule for starting and no taper schedule for stopping. If you take Ozempic for diabetes, stopping can affect your blood sugar plan, so this conversation needs your prescriber. The trial numbers above are for semaglutide 2.4 mg and tirzepatide in people without diabetes, not for Ozempic.
Stopping and starting again
If you stop and later restart, the starting doses matter. The Wegovy label says that if 2 or more doses in a row are missed, the dose escalation is restarted at a lower dose to reduce stomach side effects. The Wegovy Medication Guide asks patients who miss 2 or more weeks to contact their healthcare provider about how to restart. Do not restart at your old dose on your own. For single missed doses, see missed GLP-1 dose: what to read first.
Why to tell your prescriber before you stop
- Follow-up. In the STEP 1 extension, most of the cardiometabolic improvements seen on semaglutide moved back toward baseline within a year of stopping. Your prescriber may want to check your numbers.
- Other medicines. The labels advise considering lower doses of insulin or a sulfonylurea when starting these medicines. If you take medicines for diabetes or other conditions, your prescriber may want to review them when you stop too.
- Options. If you want to stop because of side effects, cost or supply, there may be options you have not discussed.
- A plan for after. Our guide on how to maintain weight after stopping a GLP-1 covers the general lifestyle principles from consensus sources, and how long people take a GLP-1 covers what labels say about long-term use.
When to call a clinician
Call your prescriber before stopping, and after stopping if your weight, blood pressure or blood sugar readings change.
When to call: stop the medicine and call your healthcare provider right away for severe stomach pain that will not go away, with or without vomiting, sometimes spreading to the back. Stop and get medical help right away for swelling of the face, lips, tongue or throat, or trouble breathing or swallowing. Call if you have upper stomach pain with fever, yellow skin or eyes, or clay-colored stools.
These come from the Wegovy Medication Guide and the Zepbound label. The list is not complete.
Frequently asked questions
Can you stop Zepbound cold turkey?
The Zepbound label gives no taper schedule and describes no withdrawal syndrome, and in some safety situations it says to stop right away. In SURMOUNT-4, people who stopped tirzepatide outright regained a mean 14.0% of body weight over a year. Talk to your prescriber before stopping.
How do you wean off a GLP-1?
The official labels do not describe a weaning or tapering plan, and the withdrawal trials we read did not test one. Any plan for stopping is something to build with your prescriber.
Can you stop taking Ozempic cold turkey?
The Ozempic label has no taper schedule for stopping. Ozempic is labeled for type 2 diabetes, so stopping can affect blood sugar control. Ask your prescriber before you stop.
What happens to your body when you stop a GLP-1?
The medicine leaves slowly: the Wegovy label says semaglutide stays in the blood for about 5 to 7 weeks after the last injection. In trials, weight and cardiometabolic measures tended to move back toward where they started over the following year.
Keep your own record
Dosinha’s free shot log shows your last dose and date, and the weight log and side-effect check-ins help you notice patterns to share at follow-up visits. The app does not tell you whether or how to stop. Try the free tools.
Sources
- DailyMed. Zepbound prescribing information, Wegovy prescribing information and Medication Guide and Ozempic prescribing information. Labels posted 2026.
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024.
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 2021.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
This article is for information only and is not medical advice. Talk to your prescriber or a qualified professional.